Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
234 hedge funds and large institutions have $2.26B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2016 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 73 increasing their positions, 82 reducing their positions, and 46 closing their positions.
190% more call options, than puts
Call options by funds: $253M | Put options by funds: $87.1M
11% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 46
1% more funds holding
Funds holding: 232 → 234 (+2)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
11% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 82
11% less capital invested
Capital invested by funds: $2.54B → $2.26B (-$279M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$147M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$59.6M |
| 3 |
DM
Deerfield Management
New York
|
+$45.7M |
| 4 |
JP Morgan Chase
New York
|
+$45.1M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$128M |
| 2 |
HM
HealthCor Management
New York
|
-$77.1M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$43.7M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$26.5M |
| 5 |
Goldman Sachs
New York
|
-$20.4M |
HZNP Hedge Fund Activity: Q4 2016 in Review
234 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2016, worth a combined $2.26B — down 11% from $2.54B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new HZNP positions and 46 closed out — a net gain of 5 holders — while 73 added to existing stakes and 82 trimmed.
The largest buyer was Scopia Capital Management, opening a new position worth an estimated $147M. The largest seller was Fidelity Investments, cutting an estimated $128M.
- 234 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2016, up from 232 in Q3 2016.
- Funds reported $2.26B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2016, down 11% quarter-over-quarter.
- 51 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2016 and 46 closed out, a net change of +5 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2016 was Scopia Capital Management, an estimated $147M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2016 was Fidelity Investments, an estimated $128M sold.
Based on aggregated 13F filings for Q4 2016.